Opening book details…
Can I read Targeted Delivery of Epirubicin to Tumor-associated Macrophages by Sialic Acid-cholesterol Conjugate Modified Liposomes with Improved Antitumor Activity on EtoBox?
Targeted Delivery of Epirubicin to Tumor-associated Macrophages by Sialic Acid-cholesterol Conjugate Modified Liposomes with Improved Antitumor Activity by Songlei Zhou; Ting Zhang; Bo Peng; Xiang Luo; Xinrong Liu; Ling Hu; Yang Liu; Donghua Di; Yanzhi Song; Yihui Deng is a Pharmacology, Toxicology and Pharmaceutics article available to read on EtoBox.
What is Targeted Delivery of Epirubicin to Tumor-associated Macrophages by Sialic Acid-cholesterol Conjugate Modified Liposomes with Improved Antitumor Activity about?
With the knowledge that the receptors of sialic acid are overexpressed on the surface of tumor-associated macrophages (TAMs), which play a crucial role in the tumor's progression and metastasis, a sialic acid-cholesterol conjugate (SA-CH) was synthesized and modified on the surface of epirubicin (EPI)-loaded liposomes (EPI-SAL) to improve the delivery of EPI to the TAMs. The liposomes were developed using remote loading technology via a pH gradient. The liposomes were evaluated for particle size, encapsulation efficiency, in vitro release, stability, in vitro cytotoxicity and pharmacokinetics. And the in vitro and in vivo cellular uptake studies demonstrated EPI-SAL achieved enhanced accumulation of EPI into TAMs. The antitumor studies indicated that EPI-SAL provided the strongest antitumor activity compared with the other formulations (EPI-S, EPI-CL and EPI-PL represent EPI solution, conventional liposomal EPI, PEGylated liposomal EPI, respectively), and the survival percent of tumor-bearing mice was 83.3%. The superior antitumor efficacy was probably attributed to the killing of TAMs by EPI-SAL, and modulating the tumor microenvironment with the depletion of TAMs. These findings
Who reads Targeted Delivery of Epirubicin to Tumor-associated Macrophages by Sialic Acid-cholesterol Conjugate Modified Liposomes with Improved Antitumor Activity?
It is typically read by researchers, students, and practitioners in Pharmacology, Toxicology and Pharmaceutics.
- Author
- Songlei Zhou; Ting Zhang; Bo Peng; Xiang Luo; Xinrong Liu; Ling Hu; Yang Liu; Donghua Di; Yanzhi Song; Yihui Deng
- Publisher
- Elsevier BV
- Published
- 2017
- Language
- EN
- Field
- Pharmacology, Toxicology and Pharmaceutics (Life Sciences)